2025 · 1st Quarter (Jan 1 - Mar 31)

JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES

Filed by MARSHALL & POPP, LLC.

Open official filing

Source-reported fields

Filing overview

Type: 1st Quarter - Report
Posted: Apr 21, 2025
Income: $40,000.00
Expenses: Not reported
Registrant: MARSHALL & POPP, LLC
Client: JAZZ PHARMACEUTICALS, INC. AND ITS SUBSIDIARIES, INCLUDING GREENWICH BIOSCIENCES
Filing UUID: 0228e69f-9c30-48d0-bbca-fd5f451cfc22
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to the research and development of cannabis-derived therapies and FDA's regulatory framework for CBD. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 946, Orphan Cures Act; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to the regulation of hemp-derived cannabinoids. H.R.946 - ORPHAN Cures Act.

Literal federal measure citations: H.R. 1492, H.R. 946, H.R.946

BUD · Budget/Appropriations

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

Literal federal measure citations: H.Con.Res. 14, S.Con.Res. 7

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.